Synaffix’s most recent open-access manuscript covering a 360° insight into their GlycoConnect technology for best-in-class ADCs is now published in MAbs!.
Glycostem announces new data presentation highlighting early safety and clinical course of oNKord® in patients with Acute Myeloid Leukemia
Sander van Asbeck, CEO and co-founder of RiboPro has been elected most promising entrepreneur of the year 2022. With his company, he develops messenger RNA technology for the development of new medical treatments.
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs.
Oss and Montreal, February 14, 2022. InProcess-LSP and Spectra Research Corporation (SRC) are pleased to announce they have entered into a partnership, combining SRC’s industry-leading market knowledge with InProcess’s world class and groundbreaking nanoparticle sizing technology delivering unique solutions for the particle characterization markets.
ImmunoPrecise Antibodies LTD completes acquisition of Belgian technology companies BioStrand, BioKey, and BioClue – adding artificial intelligence-driven analytics to its antibody discovery capabilities and offerings
IPA is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, and BioClue BV, a group of Belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary ImmunoPrecise Netherlands BV.
Gimv treedt toe als nieuwe investeerder in BioConnection met als doel de volgende groeifase van de onderneming te financieren en ondersteunen.
Op Pivot Park ontwikkelen ze veel meer dan geneesmiddelen. Met Leaders in Life Sciences draagt het Osse life sciences park vandaag bij aan de lancering van een podcastserie.
De groeifondsaanvraag van PharmaNL is onder voorwaarden goedgekeurd door het Nationaal Groeifonds. Dit geeft een belangrijke impuls aan nieuwe bedrijvigheid binnen de farmaceutische sector.
Henri Meijering (senior project manager at Ardena) recently co-authored a scientific article published by Clinical and Translational Science (March 2022) about Kinetics of myelin breakdown products: A labelling study in patients with progressive multiple sclerosis.
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from aberrant proliferation of T cell progenitors and accounts for 15% of pediatric ALL cases. Current standard treatment, consisting of high-dose multiagent chemotherapy, has led to an overall survival rate exceeding 80%. Nevertheless, one out of five children with T-ALL will relapse within four years after the start of therapy. New treatment options are urgently needed.
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.